upadacitinib (Rinvoq) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Upadacitinib (ABT-494) is a Janus kinase 1 (JAK1) inhibitor currently being developed by AbbVie for the treatment of rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. It is also being investigated as a potential treatment for people with active ankylosing spondylitis (AS). Currently, upadacitinib is being evaluatedin six global phase III studies in RA and twophase III studies in psoriatic arthritis (PsA), inaddition to phase II studies in Crohn’s disease and atopicdermatitis and a combined phase II/III study inulcerative colitis. Upadacitinib is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM.   NCATS

Chemistry

  • SMILES: CC[C@@H]1CN(C[C@@H]1c2cnc3cnc4[nH]ccc4n23)C(=O)NCC(F)(F)F
  • InChIKey: WYQFJHHDOKWSHR-MNOVXSKESA-N
  • Mol. Mass: 380.37
  • ALogP: 2.91
  • ChEMBL Molecules:
    upadacitinib  
    upadacitinib tartrate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$33.3409

United States

$119.5420 - $171.4803
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

abt-494 | upadacitinib | upadacitinib tartrate

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (1)


 

Colitis, Ulcerative (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Arthritis, Juvenile (Phase 1)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Axial Spondyloarthritis (Phase 3)

Biomarkers (Phase 3)

Carcinoma, Giant Cell (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Dermatitis, Atopic (Phase 3)

Hidradenitis Suppurativa (Phase 2)

Janus Kinase Inhibitors (Phase 3)

Lupus Erythematosus, Systemic (Phase 2)

Spondylarthritis (Phase 4)

Spondylitis, Ankylosing (Phase 2)

Takayasu Arteritis (Phase 3)

Ultrasonography (Phase 3)

Vitiligo (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue